November 8 2006  


 

Nucletron introduces a volume based optimization routine IPSA, which was already used for many years in its SPOT Pro system for permanent prostate planning and treatment, into its world-leading HDR and PDR Brachy planning system PLATO.


IPSA (Inverse Planning Simulated Annealing) is an anatomy-based inverse planning optimization algorithm developed by Jean Pouliot, Ph.D., Etienne Lessard, Ph.D. and I-Chow Hsu, M.D. at the University of California, San Francisco. IPSA is designed for 3D image-guided brachytherapy treatment planning and is now available for High Dose Rate brachytherapy as well.


The optimization process is guided by organ-specific dose objectives. These dose objectives are normally set to maximize the target dose coverage, while taking into account other clinical objectives such as the dose homogeneity and the protection of organs at risk. In order to solve this issue of optimization for clinical applications as efficiently as possible, a unique simulated annealing engine was designed.


IPSA allows the creation of class solutions that can be used as a starting point for every patient, thereby further reducing the time needed to plan for individual patient treatments. The concept of class solution is commonly used in IMRT.


IPSA has introduced this concept in High Dose Rate Brachytherapy. “IPSA is used for all anatomical sites typically treated with HDR brachytherapy. The general consensus is that IPSA generates plans with better dose coverage, enhanced protection to organs at risk and in a shorter time than with previous approaches,” said Jean Pouliot, PhD at University of San Francisco.


Dr. I-chow Hsu, MD at University of San Francisco quoted: “IPSA has given us improved control over dosimetry of our brachytherapy treatment. It opens the possibility to create new sophisticated treatments never considered before.”


PLATO Remote Afterloading software is Nucletron’s world leading Brachy software for High Dose Rate and Pulsed Dose Rate Brachy treatments delivered by the microSelectron HDR and PDR.



About Nucletron B.V.

Nucletron is a knowledge-based leader in Radiation Oncology, working with the clinical team to realize innovative solutions that improve patient care.


Nucletron Vision:

We strive to offer the best possible choice of treatment modality for the patient through our integrated products, software and services. We develop cancer treatment with optimal outcomes and minimal side-effects and we promote clinical acceptance of our solutions.


The company has over 20 offices worldwide, including its corporate headquarters in Veenendaal, the Netherlands. For more information on Nucletron, please have a more thourough look at this website.


Nucletron B.V. is a subsidiary of Delft Instruments. Delft Instruments is the holding company of an international group of companies that hold a leading position in their respective markets with high quality, high-technology products and services.  The Delft Instruments’ companies develop, produce, sell and service advanced (precision) hardware and software for medical and industrial customers. Medical applications include radiation treatment for cancer and ultrasound diagnostics. Industrial applications include measurement and control instrumentation for the storage and transport of oil and gas products. Delft Instruments employs some 1,100 people and reported turnover of EUR 243 million in 2005.


For more information on Delft Instruments, please visit the website at http://www.delftinstruments.com/.



For further information, please contact one of the following people:



Eric Sewsingh


Product Manager Oncentra MasterPlan
Nucletron B.V.
The Netherlands
Phone: +31 318 557 385
Email: Eric.sewsingh@nl.nucletron.com


Chandra Chatterjee, Ph.D

Product Manager Oncentra Brachy
Nucletron Corporation
Columbia, Maryland
USA
Phone: +1 410 312 4100
E-mail: Chandra.chatterjee@us.nucletron.com